Advertisement

1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances

  • Jason WallachEmail author
  • Simon D. BrandtEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 252)

Abstract

While phencyclidine (PCP) and ketamine remain the most well-studied and widely known dissociative drugs, a number of other agents have appeared since the late 1950s and early 1960s, when the pharmacological potential of this class was first realized. For example, hundreds of compounds have been pursued as part of legitimate research efforts to explore these agents. Some of these found their way out of the research labs and onto illicit markets of the 1960s and following decades as PCP analogs. Other “illicit analogs” apparently never appeared in the scientific literature prior to their existence on clandestine markets, thus originating as novel innovations in the minds of clandestine chemists and their colleagues. Like so much else in this world, new technologies changed this dynamic. In the 1990s individuals separated by vast geographical distances could now communicate nearly instantaneously with ease through the Internet. Some individuals used this newly found opportunity to discuss the chemistry and psychoactive effects of dissociative drugs as well as to collaborate on the design and development of novel dissociative compounds. Similar to modern pharmaceutical companies and academic researchers, these seekers tinkered with the structure of their leads pursuing goals such as improved duration of action, analgesic effects, and reduced toxicity. Whether all these goals were achieved for any individual compound remains to be seen, but their creations have been let out of the bag and are now materialized as defined compositions of matter. Moreover, these creations now exist not only in and of themselves but live on further as permutations into various novel analogs and derivatives. In some cases these compounds have made their way to academic labs where potential clinical applications have been identified. These compounds reached wider distribution when other individuals picked up on these discussions and began to market them as “research chemicals” or “legal highs”. The result is a continuously evolving game that is being played between legislatures, law enforcement, and research chemical market players. Two structurally distinct classes that have appeared as dissociative-based new psychoactive substances (NPS) are the 1,2-diarylethylamines and β-keto-arylcyclohexylamines. Examples of the former include diphenidine and various analogs such as fluorolintane and N-ethyl-lanicemine, and examples of the latter are analogs of ketamine such as methoxetamine, deschloroketamine, and 2-fluoro-2-deschloroketamine. The subject of this chapter is the introduction to some of the dissociative NPS from these classes and their known pharmacology that have emerged on the market in recent years.

Keywords

Clinical Designer drugs Diphenidine, ketamine analogs Dissociatives Forensic NMDA receptor Pharmacology Toxicology 

Acronyms of the Discussed New Psychoactive Substances (NPS)

2-Cl-DPP (2-Cl-DPH)

1-[1-(2-Chlorophenyl)-2-phenylethyl]piperidine

2-F-DPPy

1-[1-(2-Fluorophenyl)-2-phenylethyl]pyrrolidine (fluorolintane)

2-FDCK

2-(2-Fluorophenyl)-2-(methylamino)cyclohexan-1-one

2-MK

2-(2-Methoxyphenyl)-2-(methylamino)cyclohexan-1-one

2-MXP

1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine

2-oxo-PCA

2-Amino-2-phenylcyclohexan-1-one

2-oxo-PCE

2-(Ethylamino)-2-phenylcyclohexan-1-one

2-oxo-PCPr

2-Phenyl-2-(propylamino)cyclohexan-1-one

2-TFMDCK

2-(Methylamino)-2-[2-(trifluoromethyl)phenyl]cyclohexan-1-one

3-MeO-PCP

1-[1-(3-Methoxyphenyl)cyclohexyl]piperidine

3-MXP

1-[1-(3-Methoxyphenyl)-2-phenylethyl]piperidine

4-MeO-PV8

1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)heptan-1-one

4-MeO-PV9

1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)octan-1-one

4-MXP

1-[1-(4-Methoxyphenyl)-2-phenylethyl]piperidine

5F-ADB

Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate

5F-AMB

Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino]-3-methylbutanoate

5/6-APB

1-(1-Benzofuran-5-yl)propan-2-amine or 1-(1-benzofuran-6-yl)propan-2-amine

AB-CHMINACA

N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

AMPA

α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

AMT

1-(1H-Indol-3-yl)propan-2-amine (α-methyltryptamine)

Br-MXE

2-(2-Bromo-5-methoxyphenyl)-2-(ethylamino)cyclohexan-1-one

DCK

2-(Methylamino)-2-phenylcyclohexan-1-one

DPE (NEDPA)

N-Ethyl-1,2-diphenylethanamine (ephenidine)

DPiP (NPDPA)

N-(1,2-Diphenylethyl)propan-2-amine

DPP (1,2-DEP)

1-(1,2-Diphenylethyl)piperidine (diphenidine)

DPPy (1,2-DEPy)

1-(1,2-Diphenylethyl)pyrrolidine

FXE

2-(Ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one (fluoroxetamine)

MK-801

(+)-10,11-Dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene (dizocilpine)

MXE

2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine)

MXM (MMXE)

2-(3-Methoxyphenyl)-2-(methylamino)cyclohexan-1-one (methoxmetamine)

MXP

1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine

PCA

1-Phenylcyclohexan-1-amine

PCE

N-Ethyl-1-phenylcyclohexan-1-amine

PCP

1-(1-Phenylcyclohexyl)piperidine (phencyclidine)

PV9

1-Phenyl-2-(pyrrolidin-1-yl)octan-1-one

References

  1. Aalto S, Hirvonen J, Kajander J, Scheinin H, Någren K, Vilkman H, Gustafsson L, Syvälahti E, Hietala J (2002) Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology 164:401–406PubMedGoogle Scholar
  2. Abel KM, Allin MP, Hemsley DR, Geyer MA (2003) Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44:729–737PubMedGoogle Scholar
  3. Adamowicz P, Zuba D (2015) Fatal intoxication with methoxetamine. J Forensic Sci 60(Suppl 1):S264–S268PubMedGoogle Scholar
  4. Adams JD Jr, Baillie TA, Trevor AJ, Castagnoli N Jr (1981) Studies on the biotransformation of ketamine. 1. Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed Mass Spectrom 8:527–538PubMedGoogle Scholar
  5. Alvarez J-C, Fabresse N, Knapp A, El Hajj Sleiman I, Garnier R, Langrand J (2017) Identification and quantification of diphenidine in hair by LC-MS/MS after single administration. Toxicol Anal Clin 29:64–70Google Scholar
  6. Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bönisch H, Gautron S (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941–952PubMedGoogle Scholar
  7. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br J Pharmacol 79:565–575PubMedPubMedCentralGoogle Scholar
  8. Anonymous (1960) Pharmaceutical compositions and methods for producing phenylcyclohexane compounds. Patent No. GB853775A. Parke Davis, DetroitGoogle Scholar
  9. Anonymous (2007) Synthese von 2-Methylamino-2-phenylcyclohexanon (MPCH) [7063-30-1]. Last updated: 11 May 2007. http://www.lambdasyn.org/synfiles/mpch.htm. Accessed 26 Mar 2018
  10. Anonymous (2014) The Big & Dandy Methoxmetamine/MXM Thread - V1: Note, this is not MXE! Bluelight. http://www.bluelight.org/vb/threads/732888-The-Big-amp-Dandy-Methoxmetamine-MXM-Thread-V1-Note-this-is-not-MXE! Accessed 24 Apr 2018
  11. Anonymous (2015a) The Big & Dandy 2-Fluoroketamine Thread. Bluelight. http://www.bluelight.org/vb/threads/776753-The-Big-amp-Dandy-2-Fluoroketamine-Thread. Accessed 24 Apr 2018
  12. Anonymous (2015b) Fluorolintane. https://www.ukchemicalresearch.org/Thread-Fluorolintane. Accessed 3 Feb 2018
  13. Anonymous (2017) 2f-DCK vs DCK vs O-PCE, what do you prefer? Reddit. https://www.reddit.com/r/researchchemicals/comments/75iydc/2fdck_vs_dck_vs_opce_what_do_you_prefer/. Accessed 3 Feb 2018
  14. Aspergren BD, Heinzelman RV (1963) Therapeutic 1-(1,2-diphenylethyl) pyrrolidine for the management of depression. Patent No. US3083139. Upjohn Company, KalamazooGoogle Scholar
  15. Aspergren BD, Heinzelman RV (1964) Process for obtaining weight reduction. Patent No. US3134716. Upjohn Company, KalamazooGoogle Scholar
  16. Azzaro AJ, Smith DJ (1977) The inhibitory action of ketamine HCl on [3H]5-hydroxytryptamine accumulation by rat brain synaptosomal-rich fractions: comparison with [3H]catecholamine and [3H]γ-aminobutyric acid uptake. Neuropharmacology 16:349–356PubMedGoogle Scholar
  17. Backberg M, Jonsson KH, Beck O, Helander A (2018) Investigation of drug products received for analysis in the Swedish STRIDA project on new psychoactive substances. Drug Test Anal 10:340–349PubMedGoogle Scholar
  18. Beharry S, Gibbons S (2016) An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 267:25–34PubMedGoogle Scholar
  19. Berger ML, Schweifer A, Rebernik P, Hammerschmidt F (2009) NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. Bioorg Med Chem 17:3456–3462PubMedGoogle Scholar
  20. Berquist MD, Hyatt WS, Bauer-Erickson J, Gannon BM, Norwood AP, Fantegrossi WE (2017) Phencyclidine-like in vivo effects of methoxetamine in mice and rats. Neuropharmacology.  https://doi.org/10.1016/j.neuropharm.2017.1008.1028
  21. Boateng BO, Fever M, Edwards D, Petersson P, Euerby MR, Sutcliffe OB (2018) Chromatographic retention behaviour, modelling and optimization of a UHPLC-UV separation of the regioisomers of the Novel Psychoactive Substance (NPS) methoxphenidine (MXP). J Pharm Biomed Anal 153:238–247PubMedGoogle Scholar
  22. Botanas CJ, de la Peña JB, Dela Peña IJ, Tampus R, Yoon R, Kim HJ, Lee YS, Jang CG, Cheong JH (2015) Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: evidence of its abuse potential. Pharmacol Biochem Behav 133:31–36PubMedGoogle Scholar
  23. Botanas CJ, Bryan de la Pena J, Custodio RJ, Joy Dela Pena I, Kim M, Woo T, Kim HJ, Kim HI, Chang Cho M, Lee YS, Cheong JH (2017) Methoxetamine produces rapid and sustained antidepressant effects probably via glutamatergic and serotonergic mechanisms. Neuropharmacology 126:121–127PubMedGoogle Scholar
  24. Brunner H, Kagan HB, Kreutzer G (2003) Asymmetric catalysis. Part 153: metal-catalysed enantioselective α-ketol rearrangement. Tetrahedron Asymmetry 14:2177–2187Google Scholar
  25. Caloro M, Calabro G, de Pisa E, Rosini E, Kotzalidis GD, Lonati D, Locatelli CA, Papa P, Schifano F, Girardi P (2018) Combined NMDA inhibitor use in a patient with multisubstance-induced psychotic disorder. J Addict Med.  https://doi.org/10.1097/adm.0000000000000390 PubMedGoogle Scholar
  26. Campbell KN, Helbing CH, Florkowski MP, Campbell BK (1948) The reaction of Grignard reagents with Schiff bases. J Am Chem Soc 70:3868–3870PubMedGoogle Scholar
  27. Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, Cheer JF, Frost DO, Huang XP, Gould TD (2016) Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters. J Pharmacol Exp Ther 359:159–170PubMedPubMedCentralGoogle Scholar
  28. Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH (1999) Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry 4:274–281PubMedGoogle Scholar
  29. Champeau W, Eiden C, Gambier J, Peyriere H (2017) Methoxphenidine use disorder: first case notified to the French addictovigilance network. J Clin Psychopharmacol 37:376–377PubMedGoogle Scholar
  30. Chen G (1969) The pharmacology of ketamine. In: Kreuscher H (ed) Ketamine: Bericht über das internationale Symposion am 23. und 24. Februar 1968 in Mainz. Springer, Berlin, Heidelberg, pp 1–11Google Scholar
  31. Chen X, Shu S, Bayliss DA (2009) HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci 29:600–609PubMedPubMedCentralGoogle Scholar
  32. Cheng HC, Long JP, Van Orden LS III, Cannon JG, O’Donnell JP (1976) Dopaminergic activity of some apomorphine analogs. Res Commun Chem Pathol Pharmacol 15:89–106PubMedGoogle Scholar
  33. Chiamulera C, Armani F, Mutti A, Fattore L (2016) The ketamine analogue methoxetamine generalizes to ketamine discriminative stimulus in rats. Behav Pharmacol 27:204–210PubMedGoogle Scholar
  34. Chodoff P, Stella JG (1966) Use of CI-581: a phencyclidine derivative for obstetric anesthesia. Anesth Analg 45:527–530PubMedGoogle Scholar
  35. Chretien B, Bourgine J, Hamel Sénécal L, Bretaudeau-Deguigne M, Boels D, Lelong-Boulouard V, Le Boisselier R (2018) Severe serotonin syndrome in an autistic new psychoactive substance user after consumption of pills containing methoxphenidine and α-methyltryptamine. J Clin Psychopharmacol 38:94–96PubMedGoogle Scholar
  36. Christiaen A (1924) Contribution à l’étude de la réaction des organo-magnésiens sur les nitriles. Les nitriles α amines. Bull Soc Chim Belg 33:483–490Google Scholar
  37. Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, Ma WK, Chui KL, Yiu MK, Chan YC, Tse ML, Lau FL (2007) ‘Street ketamine’-associated bladder dysfunction: a report of ten cases. Hong Kong Med J 13:311–313PubMedGoogle Scholar
  38. Cilia J, Hatcher P, Reavill C, Jones DN (2007) (±)Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J Psychopharmacol 21:302–311PubMedGoogle Scholar
  39. Clements JA, Nimmo WS (1981) Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 53:27–30PubMedGoogle Scholar
  40. Cohen ML, Trevor AJ (1974) On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J Pharmacol Exp Ther 189:351–358PubMedGoogle Scholar
  41. Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, Westphal F, Brandt SD, Adejare A (2018) Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues. Drug Test Anal 10:272–283PubMedGoogle Scholar
  42. Coppola M, Mondola R (2012) Methoxetamine: from drug of abuse to rapid-acting antidepressant. Med Hypotheses 79:504–507PubMedGoogle Scholar
  43. Coppola M, Mondola R (2013) Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics? Med Hypotheses 81:10–14PubMedGoogle Scholar
  44. Corazza O, Assi S, Schifano F (2013) From “Special K” to “Special M”: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 19:454–460PubMedGoogle Scholar
  45. Corssen G, Domino EF (1966) Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 45:29–40PubMedGoogle Scholar
  46. Critchlow DG (2006) A case of ketamine dependence with discontinuation symptoms. Addiction 101:1212–1213PubMedGoogle Scholar
  47. Cumming JF (1976) The development of an acute tolerance to ketamine. Anesth Analg 55:788–791PubMedGoogle Scholar
  48. Dargan PI, Tang HC, Liang W, Wood DM, Yew DT (2014) Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin Toxicol (Phila) 52:176–180Google Scholar
  49. Davies SN, Alford ST, Coan EJ, Lester RA, Collingridge GL (1988) Ketamine blocks an NMDA receptor-mediated component of synaptic transmission in rat hippocampus in a voltage-dependent manner. Neurosci Lett 92:213–217PubMedGoogle Scholar
  50. Dayton PG, Stiller RL, Cook DR, Perel JM (1983) The binding of ketamine to plasma proteins: emphasis on human plasma. Eur J Clin Pharmacol 24:825–831PubMedGoogle Scholar
  51. de Bruin NM, Ellenbroek BA, Cools AR, Coenen AM, van Luijtelaar EL (1999) Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology 142:9–17PubMedGoogle Scholar
  52. De Luca MT, Badiani A (2011) Ketamine self-administration in the rat: evidence for a critical role of setting. Psychopharmacology 214:549–556PubMedGoogle Scholar
  53. Dodds EC, Lawson W, Williams PC (1944) Morphine-like properties of diphenylethylamine and related compounds. Proc R Soc Lond B Biol Sci 132:119–132Google Scholar
  54. Dodds EC, Lawson W, Simpson SA, Williams PC (1945) Testing diphenylethylamine compounds for analgesic action. J Physiol 104:47–51PubMedPubMedCentralGoogle Scholar
  55. Domino EF (2010) Taming the ketamine tiger. Anesthesiology 113:678–684PubMedGoogle Scholar
  56. Domino EF (ed) (2018) Status of ketamine in anesthesiology [reprint from 1990]. NPP Books, ArlingtonGoogle Scholar
  57. Domino EF, Chodoff P, Corssen G (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 6:279–291PubMedGoogle Scholar
  58. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM (1997) Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333:99–104PubMedGoogle Scholar
  59. Elliott SP, Brandt SD, Freeman S, Archer RP (2013) AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical challenge and implications for forensic analysis. Drug Test Anal 5:196–202PubMedGoogle Scholar
  60. Elliott SP, Brandt SD, Wallach J, Morris H, Kavanagh PV (2015) First reported fatalities associated with the ‘research chemical’ 2-methoxydiphenidine. J Anal Toxicol 39:287–293PubMedGoogle Scholar
  61. Elliott S, Sedefov R, Evans-Brown M (2018) Assessing the toxicological significance of new psychoactive substances in fatalities. Drug Test Anal 10:120–126PubMedGoogle Scholar
  62. EMCDDA (2014) Methoxetamine. Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/775/TDAK14004ENN_480922.pdf. Accessed 3 Feb 2018
  63. EMCDDA–Europol (2011) EMCDDA–Europol 2010 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/644/EMCDDA-Europol_Annual_Report_2010A_281336.pdf. Accessed 3 Feb 2018
  64. EMCDDA–Europol (2013) New drugs in Europe, 2012. EMCDDA–Europol 2012 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf. Accessed 3 Feb 2018
  65. EMCDDA–Europol (2014) EMCDDA–Europol 2013 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/814/TDAN14001ENN_475519.pdf. Accessed 3 Feb 2018
  66. EMCDDA–Europol (2015) EMCDDA–Europol 2014 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf. Accessed 3 Feb 2018
  67. EMCDDA–Europol (2016) EMCDDA–Europol 2015 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/2880/TDAS16001ENN.pdf. Accessed 3 Feb 2018
  68. EMCDDA–Europol (2017) EMCDDA–Europol 2016 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/4724/TDAN17001ENN_PDFWEB.pdf. Accessed 3 Feb 2018
  69. Energycontrol (2015) Alerta: descloroketamina vendida como ketamina en Barcelona. https://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html. Accessed 3 Feb 2018
  70. Fourcade EW, Lapidus KAB (2016) The basic and clinical pharmacology of ketamine. In: Mathew SJ, Zarate JCA (eds) Ketamine for treatment-resistant depression: the first decade of progress. Springer, Cham, pp 13–29.  https://doi.org/10.1007/978-3-319-42925-0_2 CrossRefGoogle Scholar
  71. Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG (1996) Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 117:689–697PubMedPubMedCentralGoogle Scholar
  72. Fray MJ, Bish G, Brown AD, Fish PV, Stobie A, Wakenhut F, Whitlock GA (2006a) N-(1,2-Diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett 16:4345–4348Google Scholar
  73. Fray MJ, Bish G, Fish PV, Stobie A, Wakenhut F, Whitlock GA (2006b) Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett 16:4349–4353PubMedGoogle Scholar
  74. Frison G, Zamengo L, Zancanaro F, Tisato F, Traldi P (2016) Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance. Rapid Commun Mass Spectrom 30:151–160PubMedGoogle Scholar
  75. Frohlich J, Van Horn JD (2014) Reviewing the ketamine model for schizophrenia. J Psychopharmacol 28:287–302PubMedGoogle Scholar
  76. Garcia Ruano JL, Parra A, Aleman J, Yuste F, Mastranzo VM (2009) Monoalkylation of primary amines and N-sulfinylamides. Chem Commun 404–406Google Scholar
  77. Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry 32:140–144Google Scholar
  78. Gerace E, Bovetto E, Corcia DD, Vincenti M, Salomone A (2017) A case of nonfatal intoxication associated with the recreational use of diphenidine. J Forensic Sci 62:1107–1111PubMedGoogle Scholar
  79. Geyer PM, Hulme MC, Irving JPB, Thompson PD, Ashton RN, Lee RJ, Johnson L, Marron J, Banks CE, Sutcliffe OB (2016) Guilty by dissociation – development of gas chromatography–mass spectrometry (GC-MS) and other rapid screening methods for the analysis of 13 diphenidine-derived new psychoactive substances (NPSs). Anal Bioanal Chem 408:8467–8481PubMedGoogle Scholar
  80. Ghosh P, Bolt AG, Mrongovius RI (1978) 1,2-Diphenylethylamines as potential non-stimulant anorectics. Arzneimittelforschung 28:1561–1564PubMedGoogle Scholar
  81. Goodson LH, Christopher H (1950) Diphenylethylamines.I. The preparation of tertiary amines by the Grignard reaction. J Am Chem Soc 72:358–362Google Scholar
  82. Goodson LH, Wiegand CJW, Splitter JS (1946) Analgesics. I. N-Alkylated 1,2-diphenylethylamines prepared by the Leuckart reaction. J Am Chem Soc 68:2174–2175PubMedGoogle Scholar
  83. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38:301–311PubMedGoogle Scholar
  84. Grant IS, Nimmo WS, Clements JA (1981) Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 53:805–810PubMedGoogle Scholar
  85. Gray NM, Cheng BK (1989) 1,2-Diarylethylamines for treatment of neurotoxic injury. Patent No. EP346791A1. G.D. Searle and Co., ChicagoGoogle Scholar
  86. Grumann C, Vogt S, Huppertz LM, Moosmann B, Franz F, Angerer V, Kramer L, Auwärter V (2016) Drowning due to an intoxication involving the designer drug methoxphenidine – a case report. In: Poster. 54th annual meeting of TIAFT, Brisbane, 28 Aug–1 Sept. https://www.uniklinik-freiburg.de/fileadmin/mediapool/08_institute/rechtsmedizin/pdf/Poster_2016/Grumann_-_Tiaft_2016.pdf. Accessed 3 Feb 2018
  87. Hajkova K, Jurasek B, Sykora D, Palenicek T, Miksatkova P, Kuchar M (2016) Salting-out-assisted liquid-liquid extraction as a suitable approach for determination of methoxetamine in large sets of tissue samples. Anal Bioanal Chem 408:1171–1181PubMedGoogle Scholar
  88. Halberstadt AL, Slepak N, Hyun J, Buell MR, Powell SB (2016) The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents. Psychopharmacology 233:1215–1225PubMedPubMedCentralGoogle Scholar
  89. Hansch C, Bjorkroth JP, Leo A (1987) Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci 76:663–687PubMedGoogle Scholar
  90. Harvey M, Sleigh J, Voss L, Jose J, Gamage S, Pruijn F, Liyanage S, Denny W (2015) Development of rapidly metabolized and ultra-short-acting ketamine analogs. Anesth Analg 121:925–933PubMedGoogle Scholar
  91. Hasegawa K, Wurita A, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Watanabe K, Suzuki O (2015) Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms. Forensic Toxicol 33:45–53Google Scholar
  92. Hearne E, Van Hout MC (2016) “Trip-sitting” in the black hole: a netnographic study of dissociation and indigenous harm reduction. J Psychoactive Drugs 48:233–242PubMedGoogle Scholar
  93. Heekeren K, Neukirch A, Daumann J, Stoll M, Obradovic M, Kovar KA, Geyer MA, Gouzoulis-Mayfrank E (2007) Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J Psychopharmacol 21:312–320PubMedGoogle Scholar
  94. Heinzelman RV, Aspergren BD (1953) Compounds containing the pyrrolidine ring. Analogs of sympathomimetic amines. J Am Chem Soc 75:3409–3413Google Scholar
  95. Helander A, Beck O, Bäckberg M (2015) Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol (Phila) 53:446–453Google Scholar
  96. Hesp KD, Stradiotto M (2010) Stereo- and regioselective gold-catalyzed hydroamination of internal alkynes with dialkylamines. J Am Chem Soc 132:18026–18029PubMedGoogle Scholar
  97. Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853–858PubMedGoogle Scholar
  98. Hirota K, Lambert DG (1996) Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth 77:441–444PubMedGoogle Scholar
  99. Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG (1999) Stereoselective interaction of ketamine with recombinant μ, κ, and δ opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology 90:174–182PubMedGoogle Scholar
  100. Ho JH, Dargan PI (2017) Arylcyclohexamines: ketamine, phencyclidine, and analogues. In: Brent J, Burkhart K, Dargan P et al (eds) Critical care toxicology: diagnosis and management of the critically poisoned patient. Springer, Cham, pp 1439–1484Google Scholar
  101. Hofer KE, Grager B, Müller DM, Rauber-Lüthy C, Kupferschmidt H, Rentsch KM, Ceschi A (2012) Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med 60:97–99PubMedGoogle Scholar
  102. Hofer KE, Degrandi C, Müller DM, Zürrer-Härdi U, Wahl S, Rauber-Lüthy C, Ceschi A (2014) Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine. Clin Toxicol 52:1288–1291Google Scholar
  103. Holtman JR Jr, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP (2008) Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 90:676–685PubMedGoogle Scholar
  104. Hondebrink L, Verboven AHA, Drega WS, Schmeink S, de Groot M, van Kleef R, Wijnolts FMJ, de Groot A, Meulenbelt J, Westerink RHS (2016) Neurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings. Neurotoxicology 55:1–9PubMedGoogle Scholar
  105. Hondebrink L, Kasteel EEJ, Tukker AM, Wijnolts FMJ, Verboven AHA, Westerink RHS (2017) Neuropharmacological characterization of the new psychoactive substance methoxetamine. Neuropharmacology 123:1–9PubMedGoogle Scholar
  106. Hondebrink L, Zwartsen A, Westerink RHS (2018) Effect fingerprinting of new psychoactive substances (NPS): what can we learn from in vitro data? Pharmacol Ther 182:193–224PubMedGoogle Scholar
  107. Horsley RR, Lhotkova E, Hajkova K, Jurasek B, Kuchar M, Palenicek T (2016) Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue – behavioural, pharmacokinetic and metabolic studies in the Wistar rat. Brain Res Bull 126:102–110PubMedGoogle Scholar
  108. Hungarian Institute for Forensic Science (2016) Analytical data for Deschloroketamine. Hungarian Institute for Forensic Science. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/Deschloroketamine-ID-HIFS003_rpt.pdf. Accessed 2 Apr 2018
  109. Hurt PH, Ritchie EC (1994) A case of ketamine dependence. Am J Psychiatry 151:779PubMedGoogle Scholar
  110. Hustveit O, Maurset A, Øye I (1995) Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 77:355–359PubMedGoogle Scholar
  111. Jansen KLR (2004) Ketamine: dreams and realities. Multidisciplinary Association for Psychedelic Studies, Sarasota. https://www.maps.org/images/pdf/books/K-DreamsKJansenMAPS.pdf. Accessed 8 Feb 2018
  112. Jones LE, Stewart A, Peters KL, McNaul M, Speers SJ, Fletcher NC, Bell SE (2016) Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples. Analyst 141:902–909PubMedGoogle Scholar
  113. Jordan S, Chen R, Fernalld R, Johnson J, Regardie K, Kambayashi J, Tadori Y, Kitagawa H, Kikuchi T (2006) In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors. Eur J Pharmacol 540:53–56PubMedGoogle Scholar
  114. Kaizaki-Mitsumoto A, Noguchi N, Yamaguchi S, Odanaka Y, Matsubayashi S, Kumamoto H, Fukuhara K, Funada M, Wada K, Numazawa S (2016) Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market. Forensic Toxicol 34:108–114Google Scholar
  115. Kamenka JM, Geneste P (1981) Synthesis, conformation, and physical properties of phencyclidine and its derivatives. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 47–82Google Scholar
  116. Kang H, Park P, Bortolotto ZA, Brandt SD, Colestock T, Wallach J, Collingridge GL, Lodge D (2017) Ephenidine: a new psychoactive agent with ketamine-like NMDA receptor antagonist properties. Neuropharmacology 112:144–149PubMedPubMedCentralGoogle Scholar
  117. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors-implications for models of schizophrenia. Mol Psychiatry 7:837–844PubMedGoogle Scholar
  118. Kasé Y, Yuizono T, Muto M (1963) Piperidino groups in antitussive activity. J Med Chem 6:118–122PubMedGoogle Scholar
  119. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK (2013) Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 47:710–727PubMedGoogle Scholar
  120. Keiser M, Hasan M, Oswald S (2018) Affinity of ketamine to clinically relevant transporters. Mol Pharm 15:326–331PubMedGoogle Scholar
  121. Kharasch ED, Labroo R (1992) Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 77:1201–1207PubMedGoogle Scholar
  122. Kinoshita H, Tanaka N, Takakura A, Abe H, Kumihashi M, Shibayama T, Jamal M, Ito A, Tsutsui K, Kimura S, Iwase H, Ameno K (2017) An autopsy case of death by combined use of benzodiazepines and diphenidine. Soud Lek 62:40–43PubMedGoogle Scholar
  123. Kjellgren A, Jonsson K (2013) Methoxetamine (MXE) – a phenomenological study of experiences induced by a “legal high” from the internet. J Psychoactive Drugs 45:276–286PubMedPubMedCentralGoogle Scholar
  124. Kohrs R, Durieux ME (1998) Ketamine: teaching an old drug new tricks. Anesth Analg 87:1186–1193PubMedGoogle Scholar
  125. Koike H, Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res 271:111–115PubMedGoogle Scholar
  126. Koinig H, Marhofer P, Krenn CG, Klimscha W, Wildling E, Erlacher W, Nikolic A, Turnheim K, Semsroth M (2000) Analgesic effects of caudal and intramuscular S(+)-ketamine in children. Anesthesiology 93:976–980PubMedGoogle Scholar
  127. Kokkinou M, Ashok AH, Howes OD (2018) The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry 23:59–69PubMedGoogle Scholar
  128. Kreuscher H (ed) (1969) Ketamine. Bericht über das internationale Symposion am 23. und 24. Februar 1968 in Mainz. Springer, BerlinGoogle Scholar
  129. Krupitsky EM, Burakov AM, Romanova TN, Grinenko NI, Grinenko AY, Fletcher J, Petrakis IL, Krystal JH (2001) Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology 25:936–947PubMedGoogle Scholar
  130. Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 39:13–19PubMedGoogle Scholar
  131. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214PubMedGoogle Scholar
  132. Kudo K, Usumoto Y, Kikura-Hanajiri R, Sameshima N, Tsuji A, Ikeda N (2015) A fatal case of poisoning related to new cathinone designer drugs, 4-methoxy PV8, PV9, and 4-methoxy PV9, and a dissociative agent, diphenidine. Leg Med (Tokyo) 17:421–426Google Scholar
  133. Kusano M, Zaitsu K, Taki K, Hisatsune K, Nakajima J, Moriyasu T, Asano T, Hayashi Y, Tsuchihashi H, Ishii A (2017) Fatal intoxication by 5F-ADB and diphenidine: detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q-TOFMS. Drug Test Anal.  https://doi.org/10.1002/dta.2215 PubMedGoogle Scholar
  134. Laher I, Zhang X, Leung PC, Liang W (2015) Diverse pharmacological properties of ketamine. In: Yew DT (ed) Ketamine. Use and abuse. CRC Press, Boca Raton, pp 37–63Google Scholar
  135. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9–19PubMedGoogle Scholar
  136. Lalonde BR, Wallage HR (2004) Postmortem blood ketamine distribution in two fatalities. J Anal Toxicol 28:71–74PubMedGoogle Scholar
  137. Lam RP, Yip WL, Tsui MS, Ng SW, Ching CK, Mak TW (2016) Severe rhabdomyolysis and acute kidney injury associated with methoxphenidine. Clin Toxicol (Phila) 54:464–465Google Scholar
  138. Lawn W, Borschmann R, Cottrell A, Winstock A (2016) Methoxetamine: prevalence of use in the USA and UK and associated urinary problems. J Subst Use 21:115–120Google Scholar
  139. Le Gall E, Troupel M, Nedelec JY (2006) One-step three-component coupling of aromatic organozinc reagents, secondary amines, and aromatic aldehydes into functionalized diarylmethylamines. Tetrahedron 62:9953–9965Google Scholar
  140. Leander JD, Rathbun RC, Zimmerman DM (1988) Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D-aspartic acid antagonism. Brain Res 454:368–372PubMedGoogle Scholar
  141. Li Q, Man Chan W, Rudd JA, Mei Wang C, Lam PYH, Mun Wai MS, Wood DM, Dargan PI, Yew DT (2013a) Ketamine. In: Dargan PI, Wood DM (eds) Novel psychoactive substances. Academic Press, Boston, pp 285–316Google Scholar
  142. Li Y, Coller JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, Abell AD, Somogyi AA (2013b) The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metab Dispos 41:1264–1272PubMedGoogle Scholar
  143. Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, Poon P, Coller JK, Hutchinson MR, Currow DC, Somogyi AA (2015) CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. Br J Clin Pharmacol 80:276–284PubMedPubMedCentralGoogle Scholar
  144. Licata M, Pierini G, Popoli G (1994) A fatal ketamine poisoning. J Forensic Sci 39:1314–1320PubMedGoogle Scholar
  145. Lilly JC (1996) The scientist. A metaphysical autobiography, 3rd edn. Ronin Publishing, OaklandGoogle Scholar
  146. Lim DK (2003) Ketamine associated psychedelic effects and dependence. Singap Med J 44:31–34Google Scholar
  147. Lin F, He Y, Zhang L, Zhang M, Zhang Y, Wen C (2015) Assessment of the effect of ketamine on cytochrome P450 isoforms activity in rats by cocktail method. Int J Clin Exp Med 8:4335–4341PubMedPubMedCentralGoogle Scholar
  148. Livingston A, Waterman AE (1978) The development of tolerance to ketamine in rats and the significance of hepatic metabolism. Br J Pharmacol 64:63–69PubMedPubMedCentralGoogle Scholar
  149. Lodge D, Mercier MS (2015) Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol 172:4254–4276PubMedPubMedCentralGoogle Scholar
  150. Luethi D, Hoener MC, Liechti ME (2018) Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems. Eur J Pharmacol 819:242–247PubMedGoogle Scholar
  151. MacDonald JF, Miljkovic Z, Pennefather P (1987) Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Neurophysiol 58:251–266PubMedGoogle Scholar
  152. Machado-Vieira R, Henter ID, Zarate CA Jr (2017) New targets for rapid antidepressant action. Prog Neurobiol 152:21–37PubMedGoogle Scholar
  153. MacLennan FM (1982) Ketamine tolerance and hallucinations in children. Anaesthesia 37:1214–1215PubMedGoogle Scholar
  154. Maixner J, Jurásek B, Kohout M, Kuchař M, Kačer P (2017) X-ray powder diffraction data for (S)-deschloroketamine hydrochloride, C13H18ClNO. Powder Diffract 32:193–195Google Scholar
  155. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301–307PubMedGoogle Scholar
  156. Marcsekova K, Wegener B, Doye S (2005) Ind2TiMe2-catalyzed addition of methyl- and ethylamine to alkynes. Eur J Org Chem 4843–4851Google Scholar
  157. Marietta MP, White PF, Pudwill CR, Way WL, Trevor AJ (1976) Biodisposition of ketamine in the rat: self-induction of metabolism. J Pharmacol Exp Ther 196:536–544PubMedGoogle Scholar
  158. Maskell KF, Bailey ML, Rose SR (2016) Self medication with methoxetamine as an analgesic resulting in significant toxicity. Pain Med 17:1773–1775PubMedGoogle Scholar
  159. Massmann V, Edemir B, Schlatter E, Al-Monajjed R, Harrach S, Klassen P, Holle SK, Sindic A, Dobrivojevic M, Pavenstädt H, Ciarimboli G (2014) The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflugers Arch - Eur J Physiol 466:517–527Google Scholar
  160. McCarthy DA (1981) History of the development of cataleptoid anesthetics of the phencyclidine type. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 17–24Google Scholar
  161. McCarthy DA, Chen G, Kaump DH, Ensor C (1965) General anesthetic and other pharmacological properties of 2-(O-chlorophenyl)-2-methylamino cyclohexanone HCl (CI-581). J Clin Pharmacol 5:21–33Google Scholar
  162. McLaughlin G, Morris N, Kavanagh PV, Power JD, O'Brien J, Talbot B, Elliott SP, Wallach J, Hoang K, Morris H, Brandt SD (2016) Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers. Drug Test Anal 8:98–109PubMedGoogle Scholar
  163. Mealing GA, Lanthorn TH, Small DL, Murray RJ, Mattes KC, Comas TM, Morley P (2001) Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. J Pharmacol Exp Ther 297:906–914PubMedGoogle Scholar
  164. Menzies EL, Hudson SC, Dargan PI, Parkin MC, Wood DM, Kicman AT (2014) Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine. Drug Test Anal 6:506–515PubMedGoogle Scholar
  165. Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013a) Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Anal Bioanal Chem 405:6307–6321PubMedGoogle Scholar
  166. Meyer MR, Orschiedt T, Maurer HH (2013b) Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett 217:137–142PubMedGoogle Scholar
  167. Minakata K, Yamagishi I, Nozawa H, Hasegawa K, Wurita A, Gonmori K, Suzuki M, Watanabe K, Suzuki O (2015) Diphenidine and its metabolites in blood and urine analyzed by MALDI-Q-TOF mass spectrometry. Forensic Toxicol 33:402–408Google Scholar
  168. Mion G, Villevieille T (2013) Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 19:370–380PubMedGoogle Scholar
  169. Moaddel R, Venkata SL, Tanga MJ, Bupp JE, Green CE, Iyer L, Furimsky A, Goldberg ME, Torjman MC, Wainer IW (2010) A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome. Talanta 82:1892–1904PubMedPubMedCentralGoogle Scholar
  170. Moghimi A, Rahmani S, Zare R, Sadeghzadeh M (2014) Synthesis of 2-(2-fluorophenyl)-2-methylamino-cyclohexanone as a new ketamine derivative. Synth Commun 44:2021–2028Google Scholar
  171. Moore KA, Kilbane EM, Jones R, Kunsman GW, Levine B, Smith M (1997) Tissue distribution of ketamine in a mixed drug fatality. J Forensic Sci 42:1183–1185PubMedGoogle Scholar
  172. Moreton JE, Meisch RA, Stark L, Thompson T (1977) Ketamine self-administration by the rhesus monkey. J Pharmacol Exp Ther 203:303–309PubMedGoogle Scholar
  173. Morgan CJ, Curran HV (2012) Ketamine use: a review. Addiction (Abingdon, England) 107:27–38Google Scholar
  174. Morris H (2011) Interview with a ketamine chemist or to be more precise, an arylcyclohexylamine chemist. Vice Mag 18:98–101Google Scholar
  175. Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614–632PubMedGoogle Scholar
  176. Mutti A, Aroni S, Fadda P, Padovani L, Mancini L, Collu R, Muntoni AL, Fattore L, Chiamulera C (2016) The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission. Psychopharmacology 233:2241–2251PubMedGoogle Scholar
  177. National Slovenian Forensic Laboratory (2016) Analytical report. Fluorolintane (C18H20FN). 1-(1-(2-fluorophenyl)-2-phenylethyl)pyrrolidine. National Slovenian Forensic Laboratory. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/FLUOROLINTANE-ID-1420-15-report_final.pdf. Accessed 3 Feb 2018
  178. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118PubMedGoogle Scholar
  179. Ng SH, Tse ML, Ng HW, Lau FL (2010) Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 16:6–11PubMedGoogle Scholar
  180. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS (2014) Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol 54:119–139PubMedPubMedCentralGoogle Scholar
  181. Nishimura M, Sato K (1999) Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci Lett 274:131–134PubMedGoogle Scholar
  182. Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S, Tohyama M (1998) Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88:768–774PubMedGoogle Scholar
  183. Novelli A, Huidobro H (1963) Analogues <<ouverts>> de la papavérine. Activité spasmolytique type papavérine des dériveé de la 1,2(bis-diphényl)-éthylamine. Ann Pharm Fr 21:821–827PubMedGoogle Scholar
  184. Oye I, Hustveit O, Maurset A, Ratti Moberg E, Paulsen O, Skoglund LA (1991) The chiral forms of ketamine as probes for NMDA receptor functions in humans. In: Kameyama T, Nabeshima T, Domino EF (eds) NMDA receptor related agents: biochemistry, pharmacology and behavior. NPP Books, Ann Arbor, pp 381–389Google Scholar
  185. Oye I, Paulsen O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209–1213PubMedGoogle Scholar
  186. Pal HR, Berry N, Kumar R, Ray R (2002) Ketamine dependence. Anaesth Intensive Care 30:382–384PubMedGoogle Scholar
  187. Palmer GC, Hutchison JB (1997) Preclinical and clinical aspects of remacemide hydrochloride. In: Herrling PL (ed) Excitatory amino acids. Clinical results with antagonists. Academic Press, San Diego, pp 109–120Google Scholar
  188. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239–1258PubMedGoogle Scholar
  189. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, McKenna PJ, Bullmore ET, Fletcher PC (2006) Psychological effects of ketamine in healthy volunteers: phenomenological study. Br J Psychiatry 189:173–179PubMedGoogle Scholar
  190. Preiss D, Tatar A (1995) Verwendung von 2-Methylamino-2-phenylcyclohexanon zur Behandlung von Bakterien-, Pilz-, Virus-, oder Protozoeninfektionen und zur Immunomodulation. Patent No. DE4409671. BerlinGoogle Scholar
  191. Quirion R, Hammer RP Jr, Herkenham M, Pert CB (1981) Phencyclidine (angel dust)/sigma “opiate” receptor: visualization by tritium-sensitive film. Proc Natl Acad Sci U S A 78:5881–5885PubMedPubMedCentralGoogle Scholar
  192. Rao LK, Flaker AM, Friedel CC, Kharasch ED (2016) Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance. Anesthesiology 125:1103–1112PubMedGoogle Scholar
  193. Ribeiro PO, Tome AR, Silva HB, Cunha RA, Antunes LM (2014) Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices. Brain Res 1560:10–17PubMedGoogle Scholar
  194. Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2013) The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 8:e59334PubMedPubMedCentralGoogle Scholar
  195. Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2018) Correction: the ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 13:e0194984PubMedPubMedCentralGoogle Scholar
  196. Salat K, Siwek A, Starowicz G, Librowski T, Nowak G, Drabik U, Gajdosz R, Popik P (2015) Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor. Neuropharmacology 99:301–307PubMedGoogle Scholar
  197. Salomone A, Gazzilli G, Di Corcia D, Gerace E, Vincenti M (2016) Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples. Anal Bioanal Chem 408:2035–2042PubMedGoogle Scholar
  198. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC (2014) Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19:978–985PubMedGoogle Scholar
  199. Seeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877–883PubMedGoogle Scholar
  200. Sein Anand J, Wiergowski M, Barwina M, Kaletha K (2012) Accidental intoxication with high dose of methoxetamine (MXE) – a case report. Przegl Lek 69:609–610PubMedGoogle Scholar
  201. Shahani R, Stewart RJ (2008) Reply to letter-to-the-editor, Re: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007. 71:987Google Scholar
  202. Shahani R, Streutker C, Dickson B, Stewart RJ (2007) Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69:810–812PubMedGoogle Scholar
  203. Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS (2012) Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol (Phila) 50:438–440Google Scholar
  204. Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (2016) In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J Pharmacol Exp Ther 357:134–144PubMedGoogle Scholar
  205. Slovenian National Forensic Laboratory (2016) Analytical report. Deschloro-N-ethyl-ketamine (C14H19NO). Slovenian National Forensic Laboratory. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/deschloro-N-ethyl-ketamine-ID-1607-16-rpt060816.pdf. Accessed 3 Feb 2018
  206. Smith DJ, Azzaro AJ, Zaldivar SB, Palmer S, Lee HS (1981) Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology 20:391–396PubMedGoogle Scholar
  207. Stevens CL (1962) Aminoketones and methods for their production. Patent no. US3254124A. Parke Davis, DetroitGoogle Scholar
  208. Stevens CL (1968) α-Hydroxyimines and aminoketones. Patent No. US3394182A. Parke Davis, DetroitGoogle Scholar
  209. Stevens CL, Elliott RD, Winch BL, Klundt IL (1962) A new rearrangement of α-aminoketones. J Am Chem Soc 84:2272–2274Google Scholar
  210. Stevens CL, Elliott RD, Winch BL (1963) Aminoketone rearrangements. II. The rearrangement of phenyl α-aminoketones. J Am Chem Soc 85:1464–1470Google Scholar
  211. Stevens CL, Klundt IL, Munk ME, Pillai MD (1965a) Amino ketone rearrangements. IV. Thermal rearrangements of α-amino methyl ketones. J Org Chem 30:2967–2972Google Scholar
  212. Stevens CL, Thuillier A, Daniher FA (1965b) Amino ketone rearrangements. III. The rearrangement of α-hydroxy N-phenylimines. J Org Chem 30:2962–2966Google Scholar
  213. Stevens CL, Ash AB, Thuillier A, Amin JH, Balys A, Dennis WE, Dickerson JP, Glinski RP, Hanson HT, Pillai MD, Stoddard JW (1966a) Amino ketone rearrangements. VI. Synthesis of 2-alkylamino-2-phenylcyclohexanones. J Org Chem 31:2593–2601PubMedGoogle Scholar
  214. Stevens CL, Hanson HT, Taylor KG (1966b) Amino ketone rearrangements. V. A kinetic analysis. J Am Chem Soc 88:2769–2774Google Scholar
  215. Stevens CL, Thuillier A, Taylor KG, Daniher FA, Dickerson JP, Hanson HT, Nielsen NA, Tikotkar NA, Weier RM (1966c) Amino ketone rearrangements. VII. Synthesis of 2-methylamino-2-substituted phenylcyclohexanones. J Org Chem 31:2601–2607Google Scholar
  216. Stevens CL, Cahoon JM, Potts TR, Pillai PM (1972) Epoxyamines. III. Synthesis and reactions of 2-(1-aziridinyl)-2-phenyl-3,3-dimethyloxirane and 2-(1-aziridinyl)-2-phenyl-1-oxaspiro[2.4]heptane. J Org Chem 37:3130–3133Google Scholar
  217. Stewart AT Jr, Hauser CR (1955) Synthesis and reactions of α-dialkylaminobenzyl butyl ethers. Interactions with Grignard reagents to form tertiary amines. J Am Chem Soc 77:1098–1103Google Scholar
  218. Storr TM, Quibell R (2009) Can ketamine prescribed for pain cause damage to the urinary tract? Palliat Med 23:670–672PubMedGoogle Scholar
  219. Striebel JM, Nelson EE, Kalapatapu RK (2017) “Being with a Buddha”: a case report of methoxetamine use in a United States veteran with PTSD. Case Rep Psychiatry 2017:2319094PubMedPubMedCentralGoogle Scholar
  220. Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM (2017) Effects of a ketamine metabolite on synaptic NMDAR function. Nature 546:E1–E3PubMedGoogle Scholar
  221. Svenningsson P, Nomikos GG, Greengard P (2004) Response to comment on “Diverse psychotomimetics act through a common signaling pathway”. Science 305:180Google Scholar
  222. Tainter ML, Luduena FP, Lackey RW, Neuru EN (1943) Actions of a series of diphenyl-ethylamines. J Pharmacol Exp Ther 77:317–323Google Scholar
  223. Tam SW, Zhang AZ (1988) σ and PCP receptors in human frontal cortex membranes. Eur J Pharmacol 154:343–344PubMedGoogle Scholar
  224. Tan S, Chan WM, Wai MS, Hui LK, Hui VW, James AE, Yeung LY, Yew DT (2011) Ketamine effects on the urogenital system – changes in the urinary bladder and sperm motility. Microsc Res Tech 74:1192–1198PubMedGoogle Scholar
  225. Tang HC, Lam PYH, Liang W (2015) In: Yew DT (ed) Ketamine. Use and abuse. CRC Press, Boca Raton, pp 227–242Google Scholar
  226. Taschwer M, Hofer MG, Schmid MG (2014) Enantioseparation of benzofurys and other novel psychoactive compounds by CE and sulfobutylether β-cyclodextrin as chiral selector added to the BGE. Electrophoresis 35:2793–2799PubMedGoogle Scholar
  227. Thurkauf A, Monn J, Mattson MV, Jacobson AE, Rice KC (1989) Structural and conformational aspects of the binding of aryl-alkyl amines to the phencyclidine binding site. In: Problems of drug dependence, 1989: Proceedings of the 51st annual scientific meeting, the Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph, vol 95. United States Department of Health and Human Services, National Institute on Drug Abuse, Rockville, pp 51–56Google Scholar
  228. Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY (2009) Ketamine-associated bladder dysfunction. Int J Urol 16:826–829PubMedGoogle Scholar
  229. Tso MM, Blatchford KL, Callado LF, McLaughlin DP, Stamford JA (2004) Stereoselective effects of ketamine on dopamine, serotonin and noradrenaline release and uptake in rat brain slices. Neurochem Int 44:1–7PubMedGoogle Scholar
  230. Turfus SC, Parkin MC, Cowan DA, Halket JM, Smith NW, Braithwaite RA, Elliot SP, Steventon GB, Kicman AT (2009) Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab Dispos 37:1769–1778PubMedPubMedCentralGoogle Scholar
  231. UK S.I. No. 239 (2013) The Misuse of Drugs Act 1971 (Amendment) Order 2013 (Statutory Instrument No. 239). http://www.legislation.gov.uk/uksi/2013/239/pdfs/uksi_20130239_en.pdf. Accessed 27 Mar 2018
  232. Valli A, Lonati D, Locatelli CA, Buscaglia E, Tuccio MD, Papa P (2017) Analytically diagnosed intoxication by 2-methoxphenidine and flubromazepam mimicking an ischemic cerebral disease. Clin Toxicol (Phila) 55:611–612Google Scholar
  233. Van Hout MC, Hearne E (2015) “Word of mouse”: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine. J Psychoactive Drugs 47:30–41PubMedGoogle Scholar
  234. Van Hout MC, Hearne E (2017) New psychoactive substances (NPS) on cryptomarket fora: an exploratory study of characteristics of forum activity between NPS buyers and vendors. Int J Drug Policy 40:102–110PubMedGoogle Scholar
  235. Viceland (2017) Hamilton’s pharmacopeia. Season 2. Ketamine; realms and realities. Viceland TV programme. Aired 26 Dec 2017Google Scholar
  236. Vollenweider FX, Leenders KL, Øye I, Hell D, Angst J (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25–38PubMedGoogle Scholar
  237. Vutskits L (2018) General anesthetics to treat major depressive disorder: clinical relevance and underlying mechanisms. Anesth Analg 126:208–216PubMedGoogle Scholar
  238. Wallach JV (2014) Structure activity relationship (SAR) studies of arylcyclohexylamines as N-methyl-D-aspartate receptor antagonists. Ph.D. dissertation, University of the Sciences, PhiladelphiaGoogle Scholar
  239. Wallach J, Brandt SD (2018) Phencyclidine-based new psychoactive substances. Handb Exp Pharmacol.  https://doi.org/10.1007/164_2018_124 Google Scholar
  240. Wallach J, Kavanagh PV, McLaughlin G, Morris N, Power JD, Elliott SP, Mercier MS, Lodge D, Morris H, Dempster NM, Brandt SD (2015) Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers. Drug Test Anal 7:358–367PubMedGoogle Scholar
  241. Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt AL, Brandt SD, Adejare A (2016) Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One 11:e0157021PubMedPubMedCentralGoogle Scholar
  242. Wang S, Li C (1987) Synthesis of anesthetic compound 2-(O-fluorophenyl)-2-methylamino-cyclohexanone hydrochloride (F-ketamine). Acta Sci Nat Univ Pekin 116–119Google Scholar
  243. Wang Q, Wu Q, Wang J, Chen Y, Zhang G, Chen J, Zhao J, Wu P (2017) Ketamine analog methoxetamine induced inflammation and dysfunction of bladder in rats. Int J Mol Sci 18:E117PubMedGoogle Scholar
  244. Ward J, Rhyee S, Plansky J, Boyer E (2011) Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila) 49:874–875Google Scholar
  245. Watterson J (2015) Postmortem toxicology of ketamine. In: Yew DT (ed) Ketamine. Use and abuse. CRC Press, Boca Raton, pp 243–248Google Scholar
  246. Weiner AL, Vieira L, McKay CA, Bayer MJ (2000) Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 18:447–451PubMedGoogle Scholar
  247. Weiß JA, Mohr S, Schmid MG (2015) Indirect chiral separation of new recreational drugs by gas chromatography-mass spectrometry using trifluoroacetyl-L-prolyl chloride as chiral derivatization reagent. Chirality 27:211–215PubMedGoogle Scholar
  248. Westphal F, Junge T, Jacobsen-Bauer A, Rösner P (2010) Lefetamin-Derivate: alte Bekannte neu auf dem Drogenmarkt. Toxichem Krimtech 77:46–58Google Scholar
  249. WHO (2014) Methoxetamine. Critical review report. Agenda item 4.22. In: Expert Committee on Drug Dependence thirty-sixth meeting, World Health Organization, Geneva, 16–20 June 2014. http://www.who.int/medicines/areas/quality_safety/4_22_review.pdf. Accessed 3 Feb 2018
  250. WHO (2015) MT-45. Critical review report agenda item 5.1. In: Expert Committee on Drug Dependence thirty-seventh meeting, World Health Organization, Geneva, 16–20 Nov 2015. http://www.who.int/medicines/access/controlled-substances/5.1_MT-45_CRev.pdf. Accessed 27 Mar 2018
  251. Wieber J, Gugler R, Hengstmann JH, Dengler HJ (1975) Pharmacokinetics of ketamine in man. Anaesthesist 24:260–263PubMedGoogle Scholar
  252. Wikstrom M, Thelander G, Dahlgren M, Kronstrand R (2013) An accidental fatal intoxication with methoxetamine. J Anal Toxicol 37:43–46PubMedGoogle Scholar
  253. Wink CS, Meyer GM, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (2014) Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MS and LC-HR-MS/MS. Drug Test Anal 6:1038–1048PubMedGoogle Scholar
  254. Wink CSD, Meyer GMJ, Meyer MR, Maurer HH (2015) Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. Toxicol Lett 238:39–44PubMedGoogle Scholar
  255. Wink CS, Michely JA, Jacobsen-Bauer A, Zapp J, Maurer HH (2016) Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MS(n), and LC-HR-MS(n). Drug Test Anal 8:1005–1014PubMedGoogle Scholar
  256. Winstock AR, Lawn W, Deluca P, Borschmann R (2016) Methoxetamine: an early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample. Drug Alcohol Rev 35:212–217PubMedGoogle Scholar
  257. Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI (2012) Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol 68:853–856PubMedGoogle Scholar
  258. Xie L-G, Dixon DJ (2017) Tertiary amine synthesis via reductive coupling of amides with Grignard reagents. Chem Sci 8:7492–7497PubMedPubMedCentralGoogle Scholar
  259. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T (2001) Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887–890PubMedGoogle Scholar
  260. Yeung LY, Rudd JA, Lam WP, Mak YT, Yew DT (2009) Mice are prone to kidney pathology after prolonged ketamine addiction. Toxicol Lett 191:275–278PubMedGoogle Scholar
  261. Yuizono T, Matsuo S, Nakama M, Kase Y, Fujimura H (1970) Chemico-pharmacological studies on antitussives. X. Pharmacological studies on 1,2-diphenyl-1-tert-aminoethane derivatives. Comparison of the optical isomers of 1,2-diphenyl-1-pyrrolidinoethane. Yakugaku Zasshi 90:24–31PubMedGoogle Scholar
  262. Zanda MT, Fadda P, Chiamulera C, Fratta W, Fattore L (2016) Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Behav Pharmacol 27:489–496PubMedGoogle Scholar
  263. Zanda MT, Fadda P, Antinori S, Di Chio M, Fratta W, Chiamulera C, Fattore L (2017) Methoxetamine affects brain processing involved in emotional response in rats. Br J Pharmacol 174:3333–3345PubMedPubMedCentralGoogle Scholar
  264. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481–486PubMedPubMedCentralGoogle Scholar
  265. Zanos P, Thompson SM, Duman RS, Zarate CA Jr, Gould TD (2018) Convergent mechanisms underlying rapid antidepressant action. CNS Drugs.  https://doi.org/10.1007/s40263-40018-40492-x
  266. Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, Moaddel R, Wainer IW (2012) Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331–338PubMedPubMedCentralGoogle Scholar
  267. Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA (2013) A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74:257–264PubMedGoogle Scholar
  268. Zawilska JB (2014) Methoxetamine – a novel recreational drug with potent hallucinogenic properties. Toxicol Lett 230:402–407PubMedGoogle Scholar
  269. Zeilhofer HU, Swandulla D, Geisslinger G, Brune K (1992) Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol 213:155–158PubMedGoogle Scholar
  270. Zhang DX, Levy WB (1992) Ketamine blocks the induction of LTP at the lateral entorhinal cortex-dentate gyrus synapses. Brain Res 593:124–127PubMedGoogle Scholar
  271. Zhang JC, Li SX, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141PubMedGoogle Scholar
  272. Zwartsen A, Verboven AHA, van Kleef R, Wijnolts FMJ, Westerink RHS, Hondebrink L (2017) Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. Toxicol In Vitro 45:60–71PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, Philadelphia College of PharmacyUniversity of the SciencesPhiladelphiaUSA
  2. 2.School of Pharmacy and Biomolecular SciencesLiverpool John Moores UniversityLiverpoolUK

Personalised recommendations